A Controversial Vaccine Study Sparks Ethical Concerns: Are African Newborns Being Put at Risk?
In a move that has ignited fierce debate, the Trump administration has quietly awarded a $1.6 million contract to a Danish research team to conduct a hepatitis B vaccine study on newborns in Guinea-Bissau, West Africa. But here's where it gets controversial: this no-bid contract, bypassing standard ethical reviews, involves withholding a proven vaccine from some infants in a region where hepatitis B is rampant. This has led to comparisons with the infamous Tuskegee Syphilis Study, where vulnerable populations were denied treatment for the sake of research.
The study, led by Christine Stabell Benn and her husband Peter Aaby of the University of Southern Denmark, aims to track 14,000 newborns over five years. Half will receive the hepatitis B vaccine at birth, while the other half will not. Researchers will monitor the children for death, illness, and developmental outcomes. And this is the part most people miss: the first 500 enrolled will be followed for five years to assess behavioral and brain development, but the majority will only be tracked for two years, primarily for side effects.
Hepatitis B, a potentially deadly liver infection, can be transmitted from mother to child or through contact with infected individuals. The vaccine, widely recognized by the medical community as safe and effective, has been a cornerstone of newborn health since the CDC recommended it in 1991. Yet, this study raises alarms by denying it to some of the most vulnerable—Black infants in an impoverished nation.
Why is this happening? The researchers argue that Guinea-Bissau currently does not recommend a birth dose of the hepatitis B vaccine, creating a unique opportunity to study its long-term effects before universal vaccination begins in 2027. However, critics like Dr. Boghuma K. Titanji, an infectious diseases expert from Cameroon, call the study “unconscionable,” warning it could fuel vaccine hesitancy in Africa and beyond. “There’s so much potential for this to be a harmful study,” she said.
Adding to the controversy, the study’s leaders have ties to U.S. Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic. Kennedy recently appointed Benn to a committee that voted against recommending the hepatitis B vaccine for all U.S. newborns. This connection has led some to question whether the study is scientifically driven or politically motivated.
But here’s the bigger question: Is it ethical to withhold a life-saving vaccine from at-risk infants for research purposes? Critics compare it to Tuskegee, where Black men were left untreated for syphilis. “It is an apt comparison,” Titanji noted, highlighting the moral dilemma of watching preventable suffering.
The study was approved by Guinea-Bissau’s national ethics committee but bypassed the CDC’s customary review process. CDC staffers, speaking anonymously, expressed outrage, with some labeling the study “grossly unethical.” HHS spokesman Andrew Nixon assured the public that “the highest scientific and ethical standards will be met,” but skepticism remains.
Past research by Benn and Aaby has faced scrutiny. Danish peers have flagged questionable practices, and former CDC Director Dr. Tom Frieden called a 2017 study by the pair “fundamentally flawed.” Critics like Carl Bergstrom, an evolutionary biologist, and Dr. Angela Rasmussen, a virus expert, have slammed the award, with Rasmussen accusing Kennedy of funneling taxpayer money to “cronies.”
What do you think? Is this study a necessary scientific endeavor or a reckless gamble with vulnerable lives? Share your thoughts in the comments—we want to hear from you!
